DarioHealth Corporation (DRIO)

Top National Health Plan Extends Agreement for Mental Health and Expands Dario Partnership into Cardiometabolic Care, Demonstrating Successful Multi-Condition Growth StrategyJuly 2, 2026 7:30 AM
PR Newswire (US) Third health plan customer to expand beyond initial deployment, reinforcing Dario's land-and-expand strategy and creating significant opportunity to grow revenue within existing customer baseNEW YORK, July 2, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in AI-powered digital health solutions, today announced that one of the 5 largest health insurers in the U.S. has extended its initial agreement and expanded its relationship with Dario by adding the Company's hypertension solution, following success with Dario's behavioral health offering. The health plan's roll out of Dario's cardiometabolic care significantly increases the addressable population and has the potential to approximately triple Dario's revenue opportunity under this customer relationship. Revenue contribution from the expanded program is expected in 2026, with higher impact in 2027 onward. The expansion further validates Dario's differentiated multi-condition strategy, delivering integrated care across the full clinical continuum – from prevention and rising-risk populations to members with complex chronic conditions. This whole-person approach helps health plans improve outcomes while reducing the total cost of care. The expansion marks the third health plan customer to broaden its deployment beyond an initial condition, reinforcing Dario's ability to deepen payer relationships and expand revenue within its existing customer base.Under the expanded agreement, eligible members will now also have access to Dario's AI-powered hypertension solution across the full blood pressure continuum, from pre-hypertension through Stage 2 hypertension, allowing for earlier intervention. "This expansion reflects the commercial strategy we've been executing for several years," said Erez Raphael, Chief Executive Officer of Dario. "We establish strong partnerships by delivering measurable engagement, clinical outcomes and member satisfaction, then expand those relationships across additional chronic conditions. This is now the third health plan to broaden its relationship with Dario beyond an initial deployment, further validating our multi-condition platform and our ability to grow alongside our customers."Raphael continued, "With 12 health plan customers, including 3 national carriers, 6 chronic condition solutions, and our new capabilities through Beluga's care delivery infrastructure, Dario is increasingly able to offer health plans a comprehensive, multi-condition platform that extends beyond digital engagement into provider-led clinical care."Dario's integrated platform enables health plans to deploy multiple evidence-based chronic condition programs through a unified technology platform and member experience. As payers increasingly seek comprehensive solutions that improve engagement while addressing multiple high-cost chronic conditions, Dario is well positioned to expand its footprint across existing enterprise customers including health plans and self-insured employers.About DarioHealth Corp. (NASDAQ: DRIO)DarioHealth Corp. (NASDAQ: DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multi-chronic condition digital therapeutics platform. Dario's platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health.Dario's user-centric platform offers people continuous and customized care for their health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention and results and making the right thing to do the easy thing to do.Dario provides its highly user-rated solutions globally to health plans and other payers, self-insured employers, providers of care and consumers. To learn more about Dario and its digital health solutions, or for more information, visit http://dariohealth.com.  Cautionary Note Regarding Forward-Looking StatementsThis news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it is discussing the expected revenue contribution from the expanded program, including the anticipated timing of such revenue contribution; the potential for the expanded relationship to increase the Company's revenue opportunity; the expected benefits of the expanded relationship and the Company's multi-condition platform; the Company's ability to expand relationships with existing customers and grow its customer base; the expected benefits of the Beluga care delivery infrastructure; and the Company's future growth strategy and market opportunities. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.DarioHealth Corporate ContactsMichael Lipari
SVP Corporate Development
irteam @W. Mark-785-6310Rob Halpern
SVP Marketing
irteam@dariohealth.com Logo- https://mma.prnewswire.com/media/1920436/DarioHealth_Logo.jpg View original content:https://www.prnewswire.com/news-releases/top-national-health-plan-extends-agreement-for-mental-health-and-expands-dario-partnership-into-cardiometabolic-care-demonstrating-successful-multi-condition-growth-strategy-302816343.htmlSOURCE DarioHealth Corp. Original: Top National Health Plan Extends Agreement for Mental Health and Expands Dario Partnership into Cardiometabolic Care, Demonstrating Successful Multi-Condition Growth Strategy

Dario Appoints Former Humana Chief Compliance Officer Sean O'Reilly to Advisory Board to Support Strategic Growth and Healthcare PartnershipsJune 30, 2026 7:30 AM
PR Newswire (US) O'Reilly's extensive experience across healthcare compliance, risk management, regulatory oversight and payer operations expected to support Dario's continued expansion with health plans, employers and providers as Dario moves closer to careO'Reilly's track record of leveraging advanced data analytics and AI in supporting value-based care strongly aligned with Dario's AI transitionNEW YORK, June 30, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in AI-enabled digital health solutions, today announced the appointment of Sean O'Reilly to its Advisory Board. The appointment reflects Dario's continued focus on strengthening its strategic guidance as the Company advances its channel partner-led growth strategy and moves closer to care across the payer, provider and employer markets. Mr. O'Reilly brings extensive healthcare compliance, risk management, regulatory oversight and legal experience across complex healthcare, insurance and clinical operations. He has led compliance programs supporting Medicare Advantage, Medicaid, employer group medical and specialty insurance, military healthcare, hospice and home health, value-based primary care and pharmacy benefit management organizations."Sean brings an exceptional combination of healthcare compliance leadership, operational and payer industry expertise, as well as M&A experience," stated Dario's Chief Executive Officer, Erez Raphael. "His perspective will be invaluable as we continue to expand Dario's relationships across the healthcare ecosystem, accelerate adoption of our AI-powered behavioral health and chronic multi-condition management platform, and move closer to care.""Dario is operating in one of the most important areas of healthcare, where digital engagement, clinical impact, regulatory confidence and measurable value must come together," said Mr. O'Reilly. "The Company's platform is well aligned with the needs of health plans, providers and employers seeking scalable solutions that improve outcomes while supporting accountability and operational excellence. I look forward to working with Erez and the Dario team as the Company continues to expand its role across the healthcare ecosystem."Prior to consulting in a prominent Healthcare Risk Management & Advisory practice, O'Reilly spent more than 13 years at Humana, including serving as Senior Vice President and Chief Compliance Officer, where he led enterprise compliance programs across Medicare Advantage, Medicaid, employer-sponsored health plans, pharmacy benefit management, home health, hospice, military healthcare and value-based care operations.His experience leveraging advanced data analytics and AI to strengthen compliance oversight, operational performance and value-based care aligns closely with Dario's commitment to delivering measurable healthcare outcomes through innovative technology solutions.Mr. O'Reilly is also a licensed attorney with a background in mergers and acquisitions. His work integrates privacy, ethics and technology-driven risk analysis to strengthen compliance culture, support operational integrity and enable strategic growth.About DarioHealth Corp. (NASDAQ: DRIO) DarioHealth Corp. (NASDAQ: DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multi-chronic condition digital therapeutics platform. Dario's platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health.Dario's user-centric platform offers people continuous and customized care for their health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention and results and making the right thing to do the easy thing to do.Dario provides its highly user-rated solutions globally to health plans and other payers, self-insured employers, providers of care and consumers. To learn more about Dario and its digital health solutions, or for more information, visit http://dariohealth.com.  Cautionary Note Regarding Forward-Looking StatementsThis news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when the Company's belief that Mr. O'Reilly's experience is expected to support the Company's continued expansion with health plans, employers and providers; the Company's belief that Mr. O'Reilly's appointment will strengthen its strategic guidance; the Company's expectation to continue advancing its channel partner-led growth strategy; the Company's future adoption of its AI-powered behavioral health and chronic multi-condition management platform; the Company's expectation to continue expanding its relationships across the healthcare ecosystem; the Company's expectation to continue expanding its role across the payer, provider and employer markets; the Company's belief its platform is well aligned with the needs of health plans, providers and employers; and the Company's belief its technology will continue to support measurable healthcare outcomes. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.DarioHealth Corporate ContactsMichael Lipari
SVP Corporate Development
irteam @W. Mark-785-6310Rob Halpern
SVP Marketing
irteam@dariohealth.comLogo- https://mma.prnewswire.com/media/1920436/DarioHealth_Logo.jpg  View original content:https://www.prnewswire.com/news-releases/dario-appoints-former-humana-chief-compliance-officer-sean-oreilly-to-advisory-board-to-support-strategic-growth-and-healthcare-partnerships-302813813.htmlSOURCE DarioHealth Corp. Original: Dario Appoints Former Humana Chief Compliance Officer Sean O'Reilly to Advisory Board to Support Strategic Growth and Healthcare Partnerships

Dario Presents Four Studies at American Diabetes Association Scientific Sessions Highlighting Commercial and Clinical Value of its Digital Health PlatformJune 8, 2026 8:00 AM
PR Newswire (US) Data from a total of 27 studies presented at ADA over 8 years reinforce Dario's strategic move closer to care, expanding revenue model into claims-based and outcomes-driven payments serving health plans, employers and other enterprise buyers Weight loss of 6.4% with Dario alone, and 14.3% when combined with a GLP-1 at 12 months, exceeding benchmarks based on medications alone44.8% of high-risk diabetes users achieved at least a 1% eA1c reduction at 12 monthsNEW YORK, June 8, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in global digital health, today announced presentation of four studies at the American Diabetes Association's ("ADA") Scientific Sessions highlighting the clinical and economic value of sustained engagement on its platform across high-risk cardiometabolic populations. Taken together, the studies reinforce a clear commercial message for payers, employers and other enterprise buyers: when high-risk members stay engaged with Dario's platform, outcomes improve in ways that can translate into lower cost of care, stronger member retention and greater long-term value. Across the four studies, Dario observed meaningful reductions in inpatient utilization among high-risk members with diabetes, hypertension and obesity, strong weight outcomes with and without GLP-1 therapy, improved glycemic control and a clear link between consistent engagement and better results.The findings support Dario's core enterprise thesis: sustained engagement in a single cardiometabolic digital platform can produce measurable clinical improvement across overlapping chronic conditions, while reducing avoidable utilization and the cost and complexity of managing multiple point solutions. The growing body of data including 27 studies presented at the ADA alone over the past eight years supports Dario's next strategic growth phase moving closer to care--demonstrating the platform's impact on clinical outcomes and positioning the Company to participate in the medical spend associated with those outcomes.Among the findings, when compared with the control group, participants experienced 0.23 fewer hospitalizations per patient per year ("PPPY"), highlighting Dario's potential to reduce acute healthcare utilization. In a prior Dario study, similar improvements were associated with estimated payer savings of approximately $5,077 per participant per year. Additional data showed that Dario's digital health intervention alone delivered 6.4% weight loss at 12 months, while combining Dario with GLP-1 therapy produced 14.3% weight loss, exceeding real-world pharmacotherapy-only benchmarks. Dario also found that 44.8% of high-risk diabetes users achieved at least a 1% eA1c reduction at 12 months, while consistent engagement predicted both weight loss and glycemic improvement."These studies reinforce the central promise of Dario's platform: sustained engagement can drive measurable clinical improvement in high-risk cardiometabolic populations," said Lara Dodo, Chief Operations Officer of Dario. "For enterprise buyers, the value is not just better individual outcomes. It's the ability to address diabetes, hypertension, obesity and weight management through one integrated platform rather than a fragmented set of point solutions.""What stands out across all four studies is the consistency of the signal," said Yifat Hershcovitz, PhD, VP Clinical & Scientific Affairs at Dario. "Whether the focus is utilization, weight or glycemic control, the data show that members who stay meaningfully engaged can achieve important improvements. That reinforces the value of combining personalized digital support, connected monitoring and coaching in a way that helps sustain healthy behaviors over time."The four presentations further underscore Dario's platform approach to cardiometabolic care. Dario's core capabilities include its AI-driven engagement engine, connected devices and personalized human coaching, which together are designed to support sustained behavior change across diabetes, hypertension and weight management. For enterprise customers, the findings also strengthen the case for solutions that can deliver measurable outcomes across overlapping chronic conditions rather than addressing each condition in isolation.Strategic highlights include:High-risk population impact: Demonstrated inpatient-utilization improvement in members with diabetes, hypertension and obesityEconomic relevance: Findings support the potential for avoided admission costs and broader payer savingsWeight-management performance: Strong 12-month weight outcomes both as a standalone digital intervention and in combination with GLP-1 therapyEngagement differentiation: Consistent engagement predicted stronger clinical outcomes, reinforcing Dario's platform design and long-term habit-building modelCardiometabolic breadth: Evidence of value across multiple related conditions and outcome categories within a single platformAbout DarioHealth Corp. (NASDAQ: DRIO)
DarioHealth Corp. (NASDAQ: DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multi-chronic condition digital therapeutics platform. Dario's platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health.Dario's user-centric platform offers people continuous and customized care for their health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention and results and making the right thing to do the easy thing to do.Dario provides its highly user-rated solutions globally to health plans and other payers, self-insured employers, providers of care and consumers. To learn more about Dario and its digital health solutions, or for more information, visit http://dariohealth.com. Cautionary Note Regarding Forward-Looking StatementsThis news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses the potential clinical and economic benefits of the Company's platform; the potential for sustained engagement to improve clinical outcomes, reduce healthcare utilization and lower cost of care; the potential for payer savings and member retention benefits; the expansion of its revenue model toward claims-based and outcomes-driven reimbursement opportunities; the Company's ability to participate in value-based healthcare arrangements; the scalability and effectiveness of its cardiometabolic platform; the benefits of its AI-driven engagement engine, connected devices and personalized coaching; and the Company's growth, commercialization and future revenue opportunities. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.DarioHealth Corporate ContactsMichael Lipari
SVP Corporate Development
irteam @W. Mark-785-6310Rob Halpern
SVP Marketing
irteam@dariohealth.comLogo - https://mma.prnewswire.com/media/1920436/DarioHealth_Logo.jpg View original content:https://www.prnewswire.com/news-releases/dario-presents-four-studies-at-american-diabetes-association-scientific-sessions-highlighting-commercial-and-clinical-value-of-its-digital-health-platform-302793052.htmlSOURCE DarioHealth Corp. Original: Dario Presents Four Studies at American Diabetes Association Scientific Sessions Highlighting Commercial and Clinical Value of its Digital Health Platform

DarioHealth Reports First Quarter 2026 Financial and Operating ResultsMay 13, 2026 6:30 AM
PR Newswire (US) First quarter 2026 revenues increased to $5.6 million, marking the second consecutive quarter of sequential growthOperating expenses decreased by 21% year-over-year and decreased by 8% quarter-over-quarterOperating loss decreased by 22% year-over-year and decreased by 15% quarter-over-quarter; Non-GAAP operating loss decreased by 8% year-over-year and decreased by 11% quarter-over-quarterChannel partnerships through Solera, Amwell and other blue-chip partners provide access to over 116 million covered livesNow in contracting phase with new channel partner that, upon finalization, would extend Dario's reach to a combined 175+ million covered lives and add one of the largest hospital networks in the northeastern U.S. as a day-one anchor account10 new accounts added during the first quarter ended March 31, 2026 — all outside the normal benefit cycle; Approximately $127 million pipeline across 241 active potential opportunitiesNEW YORK, May 13, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today announced financial results for the first quarter ended March 31, 2026. "The first quarter of 2026 was our second consecutive quarter of sequential revenue growth, alongside continued reductions in operating expenses. Our channel partner ecosystem now provides access to more than 116 million covered lives through blue-chip partners such as Solera and Amwell. These relationships are expanding our reach into leading national and regional payer organizations across the U.S., while strengthening our ability to scale through trusted, established market access channels," said Erez Raphael, Dario's Chief Executive Officer."In a strategic move, we are also moving closer to care, backed by more than 100 peer-reviewed clinical studies, which we believe expands both our role and our revenue model into claims-based and outcomes-driven payments. This move broadens our platform toward clinical gap closure and care delivery, with the potential of positioning Dario across a larger share of the healthcare workflow and associated spend, while continuing to grow our subscription-based annual recurring revenue contracts," Raphael added.Underpinning this strategy, DarioIQ™ — Dario's proprietary artificial intelligence ("AI") layer, operating on 13 billion real-world data points generated through U.S. Food and Drug Administration-cleared connected devices — continued to show meaningful performance during the first quarter of 2026, with behavior-triggered engagement programs now delivering up to a 40% improvement in member retention and up to a 57% lift in active sessions versus control. The combination of proprietary data, a regulated device-to-data pipeline, and a continuously learning AI layer represents a competitive moat that is difficult to replicate.Steven Nelson, Dario's President and Chief Commercial Officer, commented, "Our channel-led commercial model is producing the compounding effect we built it for. With 10 new accounts all off cycle already added in the first quarter of 2026 and several large, contracted enterprise implementations coming in the second half of the year, we believe that we are reaching the phase where our 2025 sales execution translates into meaningful scale."First Quarter 2026 Financial HighlightsRevenue of $5.6 million, increased from $5.2 million in the fourth quarter of 2025 — the second consecutive quarter of sequential growthGAAP gross margin of 57%; Non-GAAP business-to-business-to-consumer ("B2B2C") gross margin of approximately 80% for the ninth consecutive quarterOperating expenses of $10.5 million, decreased by 21% year-over-year and decreased by 8% sequentially; operating loss of $7.3 million, decreased by 22% year-over-year and decreased by 15% sequentiallyCash and short-term deposits of $20 million; net cash used in operations of $6 million, decreased by 10% year-over-year."We delivered a second consecutive quarter of sequential revenue growth with sustained B2B2C gross margins, while further reducing operating expenses. With our cash position and continued cost discipline, we believe that we are well positioned to expand our operating leverage," said Chen Franco Yehuda, Dario's Chief Financial Officer.Financial Results for the Three Months Ended March 31, 2026Revenue for the three months ended March 31, 2026 was $5.6 million, compared to $6.8 million, for the three months ended March 31, 2025, and $5.2 million for the three months ended December 31, 2025. The year-over-year decrease was primarily attributable to the non-recurrence of $1.3 million in revenues from a pharmaceutical customer recognized in the prior-year period before Dario transitioned away from one-time and non-recurring revenues to its focus on building annual recurring revenues from its core B2B2C business. The decline was partially offset by growth in channel partner revenues — including increased contributions from Solera — and continued expansion in direct to consumer musculoskeletal ("MSK") product sales. On a sequential basis, revenues increased by 6.7% from the fourth quarter of 2025, driven by onboarding of new clients coming from channel partners and increased sales of MSK product, marking the second consecutive quarter of quarter-over-quarter revenue growth.Gross profit for the three months ended March 31, 2026 was $3.2 million, compared to gross profit of $3.9 million for the three months ended March 31, 2025, and gross profit of $2.8 million for the three months ended December 31, 2025. Gross margin remained substantially stable year-over-year, resulting mainly from the change in revenue, offset by lower amortization of technology expenses recorded in the cost of revenues. On a sequential basis, gross margin improved from the fourth quarter of 2025, driven mainly by higher revenues and lower hosting and server expenses. Gross profit as a percentage of revenue was 57% in the three months ended March 31, 2026, compared to 58% in the three months ended March 31, 2025, and up from 54% in the three months ended December 31, 2025.Non-GAAP gross profit, excluding $0.2 million of amortization, stock-based compensation and depreciation, was $3.4 million, or 61% of revenues, for the three months ended March 31, 2026, compared to non-GAAP gross profit of $4.8 million, or 71% of revenues, for the three months ended March 31, 2025, and non-GAAP gross profit of $3.0 million, or 57% of revenues, for the three months ended December 31, 2025.Total operating expenses for the three months ended March 31, 2026, were $10.5 million compared to $13.3 million for the three months ended March 31, 2025, and $11.4 million for the three months ended December 31, 2025, representing a decrease of $2.8 million, or 21%, compared to the three months ended March 31, 2025, and a decrease of $0.9 million, or 8%, compared to the three months ended December 31, 2025. The year-over-year and sequential decrease in operating expenses resulted mainly from increased operational efficiency.Non-GAAP operating expenses (excluding stock-based compensation, depreciation and amortization expenses) for the three months ended March 31, 2026, were $8.7 million compared to $10.6 million for the three months ended March 31, 2025, and $9.0 million for the three months ended December 31, 2025, representing a decrease of 18% and 3%, respectively.Operating loss for the three months ended March 31, 2026 was $7.3 million, a decrease of $2.1 million, or 22%, compared to $9.4 million for the three months ended March 31, 2025, and a decrease of $1.3 million or 15% from $8.6 million for the three months ended December 31, 2025. The decrease in operating loss year-over-year and quarter-over-quarter was mainly due to an increase in operational efficiencies and post-merger integration activities.Non-GAAP operating loss (excluding stock-based compensation, and depreciation and amortization) for the three months ended March 31, 2026 was $5.3 million, representing an 8% decrease compared to a Non-GAAP operating loss of $5.8 million for the three months ended March 31, 2025, and 11% compared to a Non-GAAP operating loss of $6.0 million for the three months ended December 31, 2025.Net loss was $8.2 million for the three months ended March 31, 2026, a decrease of $1 million or 11% compared to a net loss of $9.2 million for the three months ended March 31, 2025, and a decline of $0.8 million or 9% from $9.0 million for three months ended December 31, 2025. Net loss decreased year-over-year and quarter-over-quarter due to lower operating expenses, partially offset by financial income that related to the revaluation of warrants.Non-GAAP net loss (excluding stock-based compensation, depreciation and amortization expenses) for the three months ended March 31, 2026 increased by 12% to $6.3 million compared to a non-GAAP net loss of $5.6 million for the three months ended March 31, 2025, and decreased by 3% quarter-over-quarter from a Non-GAAP net loss of $6.5 million in the three months ended December 31, 2025.A reconciliation of GAAP to non-GAAP measures has been provided in the financial statement tables included in this press release. An explanation of these measures is also included below under the heading "Non-GAAP Financial Measures." Conference Call DetailsDate: Wednesday, May 13th, 2026, 8:30 a.m. Eastern TimeDial-in Number: 1-800-717-1738 (domestic) or 1-646-307-1865 (international)Call me™:  https://emportal.ink/4seOwJKParticipants can use the dial-in numbers above and be answered by an operator OR click the Call me™ link for instant telephone access to the event. This link will be made active 15 minutes prior to the scheduled start time.Webcast link: https://viavid.webcasts.com/starthere.jsp?ei=1756269&tp_key=7306dc53e7Participants are asked to dial in approximately 10 minutes prior to the start of the event. A replay of the call will be available approximately three hours after completion of the conference call through Wednesday, May 27th, 2026. To listen to the replay, dial 1-844-512-2921 (domestic) or 1-412-317-6671 (international) and use replay passcode 1111468.About DarioHealth Corp. (NASDAQ: DRIO)DarioHealth Corp. (Nasdaq: DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multi-chronic condition digital therapeutics platform. Dario's platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health.Dario's user-centric platform offers people continuous and customized care for their health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention and results and making the right thing to do the easy thing to do.Dario provides its highly user-rated solutions globally to health plans and other payers, self-insured employers, providers of care and consumers. To learn more about Dario and its digital health solutions, or for more information, visit http://dariohealth.com.Cautionary Note Regarding Forward-Looking StatementsThis news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses expectations regarding recurring revenue contribution from agreements signed in 2025, potential future growth trajectory and scaling opportunities, the expected expansion of channel partner reach and covered lives, the potential addition of a major northeastern U.S. hospital network as an anchor account, expectations regarding the conversion of pipeline opportunities into revenue, expectations for continued sequential revenue growth, the belief that DarioIQ™ engagement programs may improve member retention and active sessions, expectations regarding expansion into claims-based and outcomes-driven payment models, expectations regarding continued growth in subscription-based annual recurring revenue contracts, the belief that channel-led commercial strategy may drive increased scale and operating leverage, and the belief that it is well positioned to expand its operating leverage due to its cash position and continued cost discipline. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.Non-GAAP Financial MeasuresThis release includes financial measures that are not prepared in accordance with U.S. GAAP. Management uses these non-GAAP measures internally to evaluate ongoing operating performance and believes they provide investors with additional insight when used as a supplement to GAAP measures. Non-GAAP measures should not be considered in isolation from, or as a substitute for, GAAP measures. A reconciliation of GAAP to non-GAAP measures is provided in the financial tables included in this release.Operating expenses (non-GAAP). Our presentation of non-GAAP operating expenses excludes stock-based compensation expenses, amortization of acquisition-related expenses and depreciation of fixed assets. Due to varying available valuation methodologies, subjective assumptions, and the variety of equity instruments that can impact a company's non-cash operating expenses, we believe that providing non-GAAP financial measures that exclude non-cash expenses provides us with an important tool for financial and operational decision making and for evaluating our own core business operating results over different periods of time.Net loss (non-GAAP). Our presentation of adjusted net loss excludes the effect of certain items that are non-GAAP financial measures. Adjusted net loss represents net loss determined under GAAP without regard to stock-based compensation expenses, depreciation and impairment expense, amortization of acquired technology and brand, financial (income) expenses, net, income tax, and acquisition costs. We believe these measures provide useful information to management and investors for analysis of our operating results.DarioHealth Corporate Contact
Zoe Harrison
VP, Accounting and Corporate Development
irteam@dariohealth.comDarioHealth Investor Relations Contact
Michael Lipari
SVP Corporate Development
irteam @W. Mark-785-6310 DARIOHEALTH CORP. AND ITS SUBSIDIARIESCONSOLIDATED BALANCE SHEETSU.S. dollars in thousands (except stock and per share data)   















March 31, 
December 31, 

2026
2025ASSETS












CURRENT ASSETS:





Cash and cash equivalents
$14,977
$21,803Short-term bank deposits

5,035

4,214Short-term restricted bank deposits

252

229Trade receivables, net

2,219

2,144Inventories

4,172

4,316Other accounts receivable and prepaid expenses

2,079

2,361






Total current assets

28,734

35,067






NON-CURRENT ASSETS:





Deposits

80

80Operating lease right of use assets

607

717Long-term assets

454

304Property and equipment, net

511

549Intangible assets, net

15,468

15,931Goodwill

57,427

57,427






Total non-current assets

74,547

75,008






Total assets
$103,281
$110,075 The accompanying notes are an integral part of the unaudited condensed consolidated interim financial statements. DARIOHEALTH CORP. AND ITS SUBSIDIARIESCONSOLIDATED BALANCE SHEETSU.S. dollars in thousands (except stock and per share data)   















March 31, 
December 31, 

2026
2025LIABILITIES AND STOCKHOLDERS' EQUITY












CURRENT LIABILITIES:





Trade payables
$3,468
$2,928Deferred revenues

501

714Operating lease liabilities

378

430Other accounts payable and accrued expenses

5,010

5,251






Total current liabilities

9,357

9,323






NON-CURRENT LIABILITIES





Operating lease liabilities

507

571Long-term loan

30,931

30,747Warrant liability

23

1,466Other long-term liabilities

83

46






Total non-current liabilities

31,544

32,830






STOCKHOLDERS' EQUITY **





Common stock of $0.0001 par value - authorized: 400,000,000 shares; issued
and outstanding: 7,299,026 and 6,905,948 shares on March 31, 2026 and
December 31, 2025, respectively

4

4Additional paid-in capital

522,703

519,996Accumulated deficit

(460,327)

(452,078)






Total stockholders' equity

62,380

67,922






Total liabilities and stockholders' equity
$103,281
$110,075 The accompanying notes are an integral part of the unaudited condensed consolidated interim financial statements. DARIOHEALTH CORP. AND ITS SUBSIDIARIESCONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSSU.S. dollars in thousands (except stock and per share data)  















Three months ended

March 31, 

2026
2025Revenues:





Services
$2,826
$4,875Consumer hardware

2,758

1,877Total revenues

5,584

6,752






Cost of revenues:





Services

563

865Consumer hardware

1,644

1,130Amortization of acquired intangible assets

177

875Total cost of revenues

2,384

2,870






Gross profit

3,200

3,882






Operating expenses:





Research and development
$2,385
$4,108Sales and marketing

4,898

5,873General and administrative

3,226

3,310






Total operating expenses

10,509

13,291






Operating loss

7,309

9,409






Interest expenses

1,149

—Other financial income, net

(266)

(204)






Total financial expenses (income), net

883

(204)






Loss before taxes

8,192

9,205






Income tax (benefit)

57

22






Net loss
$8,249
$9,227






Deemed dividend
$—
$4,839






Net loss attributable to common shareholders
$8,249
$14,066






Net loss per share:












Basic and diluted loss per share of common stock
$1.25
$2.87Weighted average number of common stock used in computing basic and
diluted net loss per share**

6,582,297

2,368,516  DARIOHEALTH CORP. AND ITS SUBSIDIARIESCONSOLIDATED STATEMENTS OF CASH FLOWSU.S. dollars in thousands 















Three months ended

March 31, 

2026
2025Cash flows from operating activities:





Net loss
$(8,249)
$(9,227)Adjustments required to reconcile net loss to net cash used in operating activities:





Stock-based compensation

1,441

2,342Change in operating lease right of use assets

110

110Amortization of acquired intangible assets

463

1,162Depreciation and impairment

61

94Change in fair value of warrant liability

(177)

(1,115)Accrued interest on short term bank deposits

(21)

—Non-cash financial expenses

159

293Changes in operating assets and liabilities:





Decrease (increase) in trade receivables, net

(75)

1,597Decrease (increase) in other accounts receivable, prepaid expense and long-term assets 

269

(369)Decrease in inventories

144

130Increase (decrease) in trade payables

535

(300)Decrease in other accounts payable and accrued expenses

(341)

(1,666)Decrease in deferred revenues

(213)

(278)Decrease in operating lease liabilities

(116)

(126)Other

(15)

680






Net cash used in operating activities

(6,025)

(6,673)






Cash flows from investing activities:





Investment in short term bank deposit

(5,000)

—Proceeds from maturity of short-term bank deposit

4,200

—Purchase of property and equipment

(31)

(31)Disposals of property and equipment

5

—






Net cash used in investing activities

(826)

(31)






Cash flows from financing activities:





Proceeds from issuance of preferred stock, net of issuance costs

—

6,815






Net cash provided by financing activities

—

6,815






Increase (decrease) in cash, cash equivalents and restricted cash and cash equivalents

(6,851)

111Effect of exchange rate differences on cash, cash equivalents and restricted cash and cash
equivalents

25

(21)Cash, cash equivalents and restricted cash and cash equivalents at beginning of period

21,803

27,764Cash, cash equivalents and restricted cash and cash equivalents at end of period
$14,977
$27,854Supplemental disclosure of cash flow information:





Cash paid during the period for interest on long-term loan
$965
$937Non-cash activities:





Exercise of pre-funded warrants to common stock
$1,266
$1,750Deferred cost related to ATM offering
$137
$—Purchase of property and equipment on credit
$5
$—  Reconciliation of Operating Loss, Net Loss and Operating Expenses to AdjustedOperating Loss, Net Loss and Operating Expenses (Non-GAAP)U.S. dollars in thousands
Three months ended March 31, 2026

GAAPStock-Based
Compensation
ExpensesAmortization of
acquisition
related expenses
and depreciation
of fixed assetsNon-GAAPCost of Revenues$2,384
(5)
(180)
2,199Gross Profit
3,200
5
180
3,385








Research and development
2,385
(92)
(32)
2,261Sales and Marketing
4,898
(133)
(299)
4,466General and Administrative
3,226
(1,211)
(13)
2,002Total Operating Expenses
10,509
(1,436)
(351)
8,722Operating Loss$(7,309)
1,441
524
(5,344)Financing expenses
883
-
-
883Income Tax
57




57Net Loss$(8,249)
1,441
524
(6,284) Reconciliation of Operating Loss, Net Loss and Operating Expenses to AdjustedOperating Loss, Net Loss and Operating Expenses (Non-GAAP)U.S. dollars in thousands
Three months ended March 31, 2025

GAAPStock-Based
Compensation
ExpensesAmortization of
acquisition
related expenses
and depreciation
of fixed assetsNon-GAAPCost of Revenues$2,870
(10)
(890)
1,970Gross Profit
3,882
10
890
4,782








Research and development
4,108
(526)
(40)
3,542Sales and Marketing
5,873
(815)
(311)
4,747General and Administrative
3,310
(991)
(15)
2,304Total Operating Expenses
13,291
(2,332)
(366)
10,593Operating Loss$(9,409)
2,342
1,256
(5,811)Financing expenses
(204)
-
-
(204)Income Tax
22




22Net Loss$(9,227)
2,342
1,256
(5,629) Logo - https://mma.prnewswire.com/media/1920436/DarioHealth_Logo.jpg  View original content:https://www.prnewswire.com/news-releases/dariohealth-reports-first-quarter-2026-financial-and-operating-results-302770792.htmlSOURCE DarioHealth Corp. Original: DarioHealth Reports First Quarter 2026 Financial and Operating Results

ScamCompany they have no revenues just sell stock and reverse. Check the 10-Q

DarioHealth Reports Fourth Quarter and Full Year 2025 Financial and Operating ResultsMarch 19, 2026 6:30 AM
PR Newswire (US)

Fourth quarter 2025 revenues grew sequentially to $5.2 million as compared to $5.0 million in the third quarter of 20252025 full-year revenue was $22.4 million, compared to $27.0 million in 2024, due entirely to a scope change and nonrenewal from a single legacy client that came through the Twill, Inc. ("Twill") acquisition — unrelated to demand — partially offset by organic revenue growth The 2025 sales season — Dario's strongest on record — generated $12.9 million in contracted and late stage, annual recurring revenue ("ARR")  set to contribute revenue in 2026 and 2027 and position the Company for a high-growth trajectoryGAAP gross margins increased to 57% in 2025 from 49% in 2024 and Non-GAAP gross margins have sustained at 80% for 2 years on the core B2B2C business Fourth quarter 2025 delivered the lowest operating expense run-rate on both a GAAP and Non-GAAP basis since Twill's acquisition, reducing Non-GAAP operating expenses by 28% year-over-year, from $12.4 million to $9.0 million, leading to continued improvements in operating loss for the fourth quarter and full yearPipeline of commercial opportunities grew to $122 million as of December 31 2025, based on 200+ opportunities that are B2B2C Increased demand for Dario's musculoskeletal ("MSK") product in the B2C market, with 36% growth in the fourth quarter of 2025 and continued expansion expected in international marketsDario will host an investor conference call and webcast at 8:30 a.m. ET todayNEW YORK, March 19, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in global digital health, today announced its financial results for the fourth quarter and full-year 2025, along with strategic and commercial updates.







"2025 was our strongest commercial year on record — 85 new agreements signed and contracted and late stage ARR contracts representing $12.9 million are expected to begin converting to revenue in 2026 and 2027. Reported revenue declined due to a single legacy client loss from the Twill acquisition — a scope change and nonrenewal, but the fourth quarter already returned to sequential growth. With a pipeline of commercial opportunities expanded to $122 million, we enter 2026 with strong near-term visibility and what we believe is a compelling foundation for sustained high growth," stated Dario's CEO, Erez Raphael."As for AI, Dario owns the entire vertical value chain down to the clinical data itself – and the value of AI is determined entirely by the quality of data it runs on. Our platform spans proprietary hardware that generates continuous physiological data, intelligent personalized interventions, coaching, and analytics — all built on 13 billion real-world data points across longitudinal member journeys. We do not license our data, rent our AI, or depend on third-party content. We believe that ownership is a structural competitive advantage that strengthens with every new member and every new data point."Commercial Momentum Continues as Dario Delivers Savings to Payers and Employers & Improved Health Outcomes to Members:In 2025 Dario signed 85 new contracts, many of which are starting to contribute revenue in 2026, with average client and contract size increasing 2X-10X compared to its historical average, more than doubling its new account target for the year. The majority of new contracts were for Dario's multi-condition platforms — the primary driver behind the 2x–10x expansion in average contract size.Pipeline of commercial opportunities increased to $122 million. The pipeline is comprised of 230 opportunities, primarily business-to-business-to-consumer ("B2B2C") contracts. More than 70% of pipeline opportunities are multi-condition, reflecting materially higher average contract values per opportunity compared to single-condition point solutions.Dario delivers more clinical proof of ROI than any other digital health company with 100+ scientific studies including peer-reviewed journal publications and conference abstracts, demonstrating the Company's leadership in delivering rigorously validated outcomes for employers, health plans and their members.The launch of AI-driven DarioIQ™ reflects years of innovation in data science, engineering and clinical design backed by Dario's proprietary AI models and 13 billion real-world data points, further reinforcing Dario's position as a leader in digital health.Dario's oral GLP-1 digital health solution is positioned to amplify the positive impacts of GLP-1 medication, improving ROI for employers and health plans in one of the fastest growing expense centers for payers."We are seeing strong engagement from large payers and employers across the U.S., all focused on a single priority — reducing healthcare costs while improving member outcomes. As healthcare expenses continue to rise, digital health has become an important strategic lever for driving behavior change and delivering measurable clinical and financial results," said Steven Nelson, Dario's President and Chief Commercial Officer."What is driving growth and what makes our model structurally different is that it compounds at two levels simultaneously. At the client level, channel partnerships give us access to millions of covered lives through a single commercial relationship, eliminating the account-by-account selling that we believe limits many competitors and reduces our cost of acquisition. At the member level, our multi-condition platform means a far greater share of each client's population qualifies for Dario — resulting in more members reached, more members enrolled, and potentially more revenue generated within the same account. One expands how many accounts we can reach, while the other expands how many members we can serve within each account. That is the compounding.""Through channel partnerships with organizations such as Solera, Amwell, and leading national health plans including Aetna, we now have access to approximately 116 million covered lives. As these ecosystems expand, we anticipate that they will allow Dario to reach significantly larger populations without proportional increases in sales infrastructure.""Quarter-over-Quarter Revenue Growth and Continued Operating Expense (OpEx) Improvement:Fourth quarter revenues grew quarter-over-quarter to $5.2 million from $5.0 million in the third quarter of 2025.Gross margin increased year-over-year to 57% in 2025, from 49% in 2024.Cash and short-term deposit balance of $26 million with reduced operating expenses, growing ARR, and robust B2B2C margins.Net cash used in operating activities declined from $38.6 million in 2024 to $25.9 million in 2025, representing a 33% reduction.Operating expenses continue to decrease — fourth quarter 2025 total operating expense declined 28% to $11.4 million year-over-year and declined 9% quarter-over-quarter; full year 2025 total operating expense declined by 31% to $49.3 million compared to 2024.Continued narrowing in operating loss — fourth quarter total operating loss declined 27% to $8.6 million year-over-year and 10% quarter-over-quarter; full year 2025 operating loss declined by 37% to $36.7 million compared to 2024.Non–GAAP operating loss is expected to decrease by approximately 30% in 2026, targeting towards cashflow breakeven by mid-2027 based on large scale channel partner contracted and near-closing ARR, increasing commercial pipeline and reductions in operating expenses."Our financial trending continues to improve as operating expenses decline and our core B2B2C ARR business is contributing approximately 80% gross margins, on a non-GAAP basis" stated Chen Franco Yehuda, Dario's Chief Financial Officer. "In fact, the fourth quarter of 2025 delivered the lowest operating expense run-rate, on both a GAAP and non-GAAP basis, since the Twill acquisition. With disciplined financial controls, ongoing operating efficiencies and AI utilization, we reduced net cash used in operations, which declined by 33% year over year." Financial Results for the Three Months Ended December 31, 2025Revenue for the three months ended December 31, 2025 was $5.2 million, compared to $7.6 million, for the three months ended December 31, 2024, and $5.0 million for the three months ended September 30, 2025. The year-over-year decrease was primarily due to Dario's transition away from one-time and non-recurring revenues to its focus on building ARR revenues from its core B2B2C business and a significant scope change with a large national health plan client that came with the Twill acquisition and was not renewed in the beginning of 2025. The quarter-over-quarter increase in revenues is the result of an acceleration in new ARR revenue contracts from large employers and health plans, in line with Dario's growth strategy.Gross profit for the three months ended December 31, 2025 was $2.8 million, compared to gross profit of $4.2 million for the three months ended December 31, 2024, and gross profit of $3.0 million for the three months ended September 30, 2025. The reason for the decrease as compared to the three months ended December 31, 2024 resulted mainly from the change in revenue, partially offset by lower amortization of technology expenses record in the cost of revenues. The decrease as compared to the three months ended September 30, 2025 was primarily due to higher costs recorded in the cost of revenues. Gross profit as a percentage of revenue was 54% in the three months ended December 31, 2025, compared to 55% in the three months ended December 31, 2024, and 60% in the three months ended September 30, 2025.Non-GAAP gross profit, excluding $0.2 million of amortization expenses related to stock-based compensation and depreciation was $3.0 million, or 57% of revenues, for the three months ended December 31, 2025, compared to non-GAAP gross profit of $5.5 million, or 72% of revenues, for the three months ended December 31, 2024, and a non-GAAP gross profit of $3.2 million, or 64% of revenues, for the three months ended September 30, 2025. A reconciliation of GAAP to non-GAAP measures has been provided in the financial statement tables included in this press release. An explanation of these measures is also included below under the heading "Non-GAAP Financial Measures."Total operating expenses for the three months ended December 31, 2025, were $11.4 million compared to $15.9 million for the three months ended December 31, 2024, and $12.5 million for the three months ended September 30, 2025 a decrease of $4.5 million, or 28%, compared to the three months ended December 31, 2024, and a decrease of $1.1 million, or 9%, compared to the three months ended September 30, 2025. The year-over-year decrease in operating expenses resulted mainly from post-merger integration activities and increased operational efficiency. The quarter-over-quarter decrease was driven by continued realization of these operational efficiencies and an approximately $0.3 million Coronavirus Aid, Relief, and Economic Security (CARES) Act payment received in the three months ended December 31, 2025 which was offset from operating expenses.Non-GAAP operating expenses (excluding stock-based compensation, acquisition related expenses, depreciation and amortization expenses) for the three months ended December 31, 2025, were $9.0 million compared to $12.4 million for the three months ended December 31, 2024, and $9.2 million for the three months ended September 30, 2025, representing a decrease of 28% and 2%, respectively.Operating loss for the three months ended December 31, 2025, was $8.6 million, a decrease of $3.1 million, or 27%, compared to $11.7 million for the three months ended December 31, 2024, and a decrease of $0.9 million or 10% from $9.5 million for the three months ended September 30, 2025. The decrease in operating loss year-over-year and quarter-over-quarter, was mainly due to an increase in operational efficiencies and post-merger integration activities.Non-GAAP operating loss (excluding stock-based compensation, acquisition-related expenses, and depreciation and amortization) for the three months ended December 31, 2025 was $6.0 million, representing a 14% decrease compared to a non-GAAP operating loss of $6.9 million for the three months ended December 31, 2024, and remained flat compared to a non-GAAP operating loss of $6.0 million for the three months ended September 30, 2025.Net loss was $9.0 million for the three months ended December 31, 2025, a narrowing of $0.6 million or 6% compared to a net loss of $9.6 million for the three months ended December 31, 2024, and a decline of $1.5 million or 14% from $10.5 million for three months ended September 30, 2025. Net loss narrowed year-over-year, driven by a reduction in total operating expenses, partially offset by a financial income, primarily due to revaluation of warrants recognized in the prior-year quarter. The quarter-over-quarter improvement driven mainly by lower operating expenses.Non-GAAP net loss (excluding stock-based compensation, acquisition related expenses, depreciation and amortization expenses) for the three months ended December 31, 2025 increased by 32% to $6.5 million compared to a non-GAAP net loss of $4.9 million for the three months ended December 31, 2024, and narrowed by 7% quarter-over-quarter from a non-GAAP net loss of $7.0 million in the three months ended September 30, 2025.A reconciliation of GAAP to non-GAAP measures has been provided in the financial statement tables included in this press release. An explanation of these measures is also included below under the heading "Non-GAAP Financial Measures."Financial Results for the Year Ended December 31, 2025Revenues for the year ended December 31, 2025 were $22.4 million, compared to $27.0 million for the year ended December 31, 2024, primarily due to Dario's transition away from one-time and non-recurring revenues to its focus on building ARR revenues from its core B2B2C business and a significant scope change with a large national health plan client that came through the Twill acquisition and was not renewed in the beginning of 2025, partially offset by new ARR.Gross profit for the year ended December 31, 2025, was $12.7 million, compared to gross profit of $13.3 million for the year ended December 31, 2024. Gross profit as a percentage of revenues increased year-over-year to 57% in the year ended December 31, 2025, from 49% in the year ended December 31, 2024. The decrease in gross profit compared to the year ended December 31, 2024 resulted mainly from the decline in revenues, partially offset by lower technology amortization and other costs included in cost of revenues, which contributed to the improvement in gross profit as a percentage of revenues year-over-year.Non-GAAP gross profit, excluding $1.7 million of amortization expenses related to  stock-based compensation and depreciation, was $14.4million, or 64% of revenues, for the year ended December 31, 2025, compared to non-GAAP gross profit of $18.4 million, or 68% of revenues, for the year ended December 31, 2024. A reconciliation of GAAP to non-GAAP measures has been provided in the financial statement tables included in this press release. An explanation of these measures is also included below under the heading "Non-GAAP Financial Measures."Total operating expenses for the year ended December 31, 2025, were $49.3 million compared to $71.0 million for the year ended December 31, 2024, a decrease of $21.7 million, or 31%. The decrease in operating expenses compared to the year ended December 31, 2024, resulted mainly from increased operational efficiencies and post-merger integration activities.Non-GAAP operating expenses (excluding stock-based compensation, acquisition-related expenses, depreciation and amortization expenses) for the year ended December 31, 2025, were $38.6 million compared to $52.2 million for the year ended December 31, 2024, representing a decrease of $13.6 million.Operating loss for the year ended December 31, 2025, was $36.7 million, a decrease of $21.0 million, or 37%, compared to $57.7 million for the year ended December 31, 2024. The decrease in operating loss compared to the year ended December 31, 2024, was mainly due to an increase in operational efficiencies and post-merger integration activities.Non-GAAP operating loss (excluding stock-based compensation, acquisition related expenses, depreciation and amortization expenses) for the year ended December 31, 2025 was $24.1 million representing a decrease of 29%, compared to a non-GAAP operating loss of $33.8 million in the year ended December 31, 2024.  Net loss was $41.7 million for the year ended December 31, 2025, a decline of 2% or $1.0 million compared to a net loss of $42.7 million for the year ended December 31, 2024.Non-GAAP net loss (excluding stock-based compensation, acquisition-related expenses, and depreciation and amortization) for the year ended December 31, 2025 was $29.2 million, compared to $18.8 million for the year ended December 31, 2024. The increase in non-GAAP net loss was primarily due to the revaluation of pre-funded warrants, partially offset by a decrease in operating loss.A reconciliation of GAAP to non-GAAP measures has been provided in the financial statement tables included in this press release. An explanation of these measures is also included below under the heading "Non-GAAP Financial Measures."Conference Call DetailsDate: Thursday, March 19th, 2026, 8:30 a.m. Eastern TimeDial-in Number: 1-800-717-1738 (domestic) or 1-646-307-1865 (international)Call me™:  https://emportal.ink/4sksMwGParticipants can use the dial-in numbers above and be answered by an operator OR click the Call me™ link for instant telephone access to the event. This link will be made active 15 minutes prior to the scheduled start time.Webcast link:  https://viavid.webcasts.com/starthere.jsp?ei=1748263&tp_key=02d7c540f8Participants are asked to dial in approximately 10 minutes prior to the start of the event. A replay of the call will be available approximately three hours after completion of the conference call through Thursday, April 2nd, 2026. To listen to the replay, dial 1-844-512-2921 (domestic) or 1-412-317-6671 (international) and use replay passcode 1191893.About DarioHealth Corp. (NASDAQ: DRIO)DarioHealth Corp. (NASDAQ: DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multi-chronic condition digital therapeutics platform. Dario's platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health.Dario's user-centric platform offers people continuous and customized care for their health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention and results and making the right thing to do the easy thing to do.Dario provides its highly user-rated solutions globally to health plans and other payers, self-insured employers, providers of care and consumers. To learn more about Dario and its digital health solutions, or for more information, visit http://dariohealth.com.Cautionary Note Regarding Forward-Looking StatementsThis news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses its expectation that agreements entered into in 2025 will provide recurring revenue in 2026 and 2027, positioning the Company for a high-growth trajectory; its belief that increased demand for the Company's MSK product in the B2C market will result in expansion in international markets; its belief that the Company's model will provide compounding growth resulting in an expected increase in account outreach and growth, member enrollment and resulting revenue, increased through client collaborations and member enrollment; its belief that the Company's oral GLP-1 digital health solution is positioned to amplify the positive impacts of GLP-1 medication, improving ROI for employers and health plans; its belief that the Company's channel partnerships will expand and its expectation that such expansion will allow the Company to reach significantly larger populations without proportional increases in sales infrastructure; and its expectation that the Company will reduce its operating loss by 30% and reach cashflow breakeven by mid-2027. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.Non-GAAP Financial MeasuresWe have provided financial information in this release that has not been prepared in accordance with Generally Accepted Accounting Principles (GAAP). These non-GAAP financial measures are not based on any standardized methodology prescribed by GAAP and are not necessarily comparable to similar measures presented by other companies. We use these non-GAAP financial measures internally in analyzing our financial results and believe they are useful to investors, as a supplement to GAAP measures, in evaluating our ongoing operational performance. We believe that the use of these non-GAAP financial measures provides an additional tool for investors to use in evaluating ongoing operating results and trends and in comparing our financial results with peer companies, many of which present similar non-GAAP financial measures to investors.Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. Investors are encouraged to review the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures provided in the financial statement tables below.Operating expenses (non-GAAP). Our presentation of non-GAAP operating expenses excludes stock-based compensation expenses, amortization of acquisition-related expenses and depreciation of fixed assets. Due to varying available valuation methodologies, subjective assumptions, and the variety of equity instruments that can impact a company's non-cash operating expenses, we believe that providing non-GAAP financial measures that exclude non-cash expenses provides us with an important tool for financial and operational decision making and for evaluating our own core business operating results over different periods of time.Net loss (non-GAAP). Our presentation of adjusted net loss excludes the effect of certain items that are non-GAAP financial measures. Adjusted net loss represents net loss determined under GAAP without regard to stock-based compensation expenses, depreciation and impairment expense, amortization of acquired technology and brand, financial (income) expenses, net, income tax, and acquisition costs. We believe these measures provide useful information to management and investors for analysis of our operating results. DARIOHEALTH CORP. AND ITS SUBSIDIARIESCONSOLIDATED BALANCE SHEETS U.S. dollars in thousands

December 31, 
December 31, 

2025
2024ASSETS












CURRENT ASSETS:





Cash and cash equivalents
$21,803
$27,764Short-term bank deposits

4,214

697Short-term restricted bank deposits

229

175Trade receivables, net

2,144

4,804Inventories

4,316

4,753Other accounts receivable and prepaid expenses

2,361

2,336






Total current assets

35,067

40,529






NON-CURRENT ASSETS:





Deposits

80

79Operating lease right of use assets

717

1,065Long-term assets

304

313Property and equipment, net

549

709Intangible assets, net

15,931

18,762Goodwill

57,427

57,427






Total non-current assets

75,008

78,355






Total assets
$110,075
$118,884  DARIOHEALTH CORP. AND ITS SUBSIDIARIESCONSOLIDATED BALANCE SHEETSU.S. dollars in thousands (except stock and per share data)   

December 31, 
December 31, 

2025
2024LIABILITIES AND STOCKHOLDERS' EQUITY












CURRENT LIABILITIES:





Trade payables
$2,928
$3,045Deferred revenues

714

1,583Operating lease liabilities

430

504Other accounts payable and accrued expenses

5,251

6,052Current maturity of long-term loan

—

5,451






Total current liabilities

9,323

16,635






NON-CURRENT LIABILITIES





Operating lease liabilities

571

765Long-term loan

30,747

23,472Warrant liability

1,466

5,968Other long-term liabilities

46

25






Total non-current liabilities

32,830

30,230






STOCKHOLDERS' EQUITY





Common stock of $0.0001 par value - authorized: 400,000,000 shares; issued and
outstanding: 6,905,948 and 1,919,422 shares on December 31, 2025 and
December 31, 2024, respectively

4

4Preferred stock of $0.0001 par value - authorized: 5,000,000 shares; issued and
outstanding: 0 and 49,585 shares on December 31, 2025 and December 31, 2024,
respectively

*) -

*) -Additional paid-in capital

519,996

462,358Accumulated deficit

(452,078)

(390,343)






Total stockholders' equity

67,922

72,019






Total liabilities and stockholders' equity
$110,075
$118,884 *) Represents an amount lower than $1.  DARIOHEALTH CORP. AND ITS SUBSIDIARIESCONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSSU.S. dollars in thousands (except stock and per share data)   

Year ended

December 31,

2025
2024Revenues:





Services
$14,929
$20,197Consumer hardware

7,430

6,843Total revenues

22,359

27,040






Cost of revenues:





Services

2,900

3,606Consumer hardware

5,124

5,139Amortization of acquired intangible assets

1,670

5,028Total cost of revenues

9,694

13,773






Gross profit

12,665

13,267






Operating expenses:





Research and development
$13,791
$24,179Sales and marketing

20,338

26,350General and administrative

15,191

20,482






Total operating expenses

49,320

71,011






Operating loss

36,655

57,744






Interest expenses

3,020

—Other financial expenses (income), net

1,934

(13,145)






Total financial expenses (income), net

4,954

(13,145)






Loss before taxes

41,609

44,599






Income taxes (benefit)

105

(1,852)






Net loss
$41,714
$42,747






Deemed dividend (contribution)
$20,021
$(1,765)






Net loss attributable to common shareholders
$61,735
$40,982






Net loss per share:












Basic and diluted loss per share of common stock
$10.12
$12.27Weighted average number of common stock used in computing
basic and diluted net loss per share**

3,982,956

2,451,971  DARIOHEALTH CORP. AND ITS SUBSIDIARIESCONSOLIDATED STATEMENTS OF CASH FLOWSU.S. dollars in thousands

Year ended

December 31,

2025
2024Cash flows from operating activities:





Net loss
$(41,714)
$(42,747)Adjustments required to reconcile net loss to net cash used in operating activities:





Stock-based compensation

9,365

15,796Change in operating lease right of use assets

421

907Amortization of acquired intangible assets

2,831

6,100Changes in operating assets and liabilities, net of effects of businesses acquired:





Depreciation and impairment

307

1,327Decrease in trade receivables, net

2,660

1,680Increase in other accounts receivable, prepaid expense and long-term assets 

(16)

(80)Decrease in inventories

437

308Decrease in trade payables

(122)

(496)Decrease in other accounts payable and accrued expenses

(780)

(3,483)Decrease in deferred revenues

(869)

(156)Change in operating lease liabilities

(341)

(1,150)Change in fair value of warrant liability

(1,681)

(16,504)Accrued interest on short term bank deposits

(14)

—Non-cash financial expenses

2,933

516Other

642

(580)






Net cash used in operating activities

(25,941)

(38,562)






Cash flows from investing activities:





Purchase of property and equipment, net

(142)

(138)Investments in short-term bank deposits

(4,200)

—Payments for business acquisitions, net of cash acquired

—

(8,796)






Net cash used in investing activities

(4,342)

(8,934)






Cash flows from financing activities:





Proceeds from issuance of common stock and prefunded warrants, net of issuance costs

17,374

—Proceeds from issuance of preferred stock, net of issuance costs

6,754

38,531Proceeds from borrowings on credit agreement, net

31,700

—Repayment of long-term loan

(31,515)

—






Net cash provided by financing activities

24,313

38,531






Increase (decrease) in cash, cash equivalents and restricted cash and cash equivalents

(5,970)

(8,965)Effect of exchange rate differences on cash, cash equivalents and restricted cash and
cash equivalents

9

(68)Cash, cash equivalents and restricted cash and cash equivalents at beginning of period

27,764

36,797Cash, cash equivalents and restricted cash and cash equivalents at end of period
$21,803
$27,764Supplemental disclosure of cash flow information:





Cash paid during the period for interest on long-term loan
$3,493
$3,927Non-cash activities:





Right-of-use assets obtained in exchange for lease liabilities
$73
$428Purchase of property and equipment on credit

5

—Exercise of pre-funded warrants to common stock upon acquisition
$2,821
$2,225  Reconciliation of Operating Loss, Net Loss and Operating Expenses to AdjustedOperating Loss, Net Loss and Operating Expenses (Non-GAAP)U.S. dollars in thousands
Three months ended December 31, 2025

GAAPStock-Based
Compensation
ExpensesAmortization of
acquisition
related expenses
and depreciation
of fixed assetsNon-GAAPCost of Revenues$2,427
(4)
(184)
2,239Gross Profit
2,804
4
184
2,992








Research and development
2,634
(267)
(31)
2,336Sales and Marketing
4,630
(300)
(308)
4,022General and Administrative
4,102
(1,467)
(10)
2,625Total Operating Expenses
11,366
(2,034)
(349)
8,983Operating Loss$(8,562)
2,038
533
(5,991)Financing expenses
386
-
-
386Income Tax
83
-
-
83Net Loss$(9,031)
2,038
538
(6,460)  Reconciliation of Operating Loss, Net Loss and Operating Expenses to AdjustedOperating Loss, Net Loss and Operating Expenses (Non-GAAP)U.S. dollars in thousands
Three months ended December 31, 2024

GAAPStock-Based
Compensation
ExpensesAmortization of
acquisition
related expenses
and depreciation
of fixed assetsNon-GAAPCost of Revenues$3,402
(8)
(1,302)
2,092Gross Profit
4,202
(8)
1,302
5,512








Research and development
5,281
(985)
(51)
4,245Sales and Marketing
5,575
(536)
(325)
4,714General and Administrative
5,014
(1,061)
(474)
3,479Total Operating Expenses
15,870
(2,582)
(850)
12,438Operating Loss$(11,668)
2,590
2,152
(6,926)Financing expenses
(2,191)
-
-
(2,191)Income Tax
155
-
-
155Net Loss$(9,632)
2,590
2,152
(4,890)  Reconciliation of Operating Loss, Net Loss and Operating Expenses to AdjustedOperating Loss, Net Loss and Operating Expenses (Non-GAAP)U.S. dollars in thousands
Twelve months ended December 31, 2025
GAAPStock-Based
Compensation
ExpensesAmortization of
acquisition
related expenses
and depreciation
of fixed assetsNon-GAAPCost of Revenues$9,694
(26)
(1,713)
7,955Gross Profit
12,665
26
1,713
14,404








Research and development
(13,791)
(1,623)
(135)
(12,033)Sales and Marketing
(20,338)
(2,253)
(1,234)
(16,851)General and Administrative
(15,191)
(5,463)
(56)
(9,672)Total Operating Expenses
(49,320)
(9,339)
(1,425)
(38,556)Operating Loss$(36,655)
9,365
3,138
(24,152)Financing expenses
4,954
-
-
4,954Income Tax
105
-
-
105Net Loss$(41,714)
9,365
3,138
(29,211)  Reconciliation of Operating Loss, Net Loss and Operating Expenses to AdjustedOperating Loss, Net Loss and Operating Expenses (Non-GAAP)U.S. dollars in thousands
Twelve months ended December 31, 2024

GAAPStock-Based
Compensation
ExpensesAmortization of
acquisition
related expenses
and depreciation
of fixed assetsNon -GAAPCost of Revenues$13,773
(13)
(5,086)
8,674Gross Profit
13,267
13
5,086
18,366








Research and development
24,179
(3,296)
(238)
20,645Sales and Marketing
26,350
(4,890)
(1,183)
20,277General and Administrative
20,482
(7,597)
(1,649)
11,236Total Operating Expenses
71,011
(15,783)
(3,070)
52,158Operating Loss$(57,744)
15,796
8,156
(33,792)Financing expenses
(13,145)
-
-
(13,145)Income Tax
(1,852)
-
-
(1,852)Net Loss$(42,747)
15,796
8,156
(18,795)  DarioHealth Corporate ContactZoe Harrison
VP, Accounting and Corporate Development
irteam@dariohealth.comDarioHealth Investor Relations ContactMichael Lipari
SVP Corporate Development
irteam @W. Mark-785-6310Logo - https://mma.prnewswire.com/media/2866807/5869548/Dario_Logo.jpg



View original content to download multimedia:https://www.prnewswire.com/news-releases/dariohealth-reports-fourth-quarter-and-full-year-2025-financial-and-operating-results-302718542.htmlSOURCE DarioHealth Corp.

Original: DarioHealth Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

Dario Demonstrates Clinically Meaningful Blood Glucose Improvements and Personalized Glycemic Trajectories Across 22,000+ Users: Machine Learning Study Findings Published in Frontiers in Digital HealthMarch 10, 2026 8:00 AM
PR Newswire (US)

Findings reinforce that engagement data provide clinical signals directly impacting ROIAnalysis further reveals specific frequency of measurements that drive clinical outcomes and bend the cost curveNEW YORK, March 10, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in global digital health, today announced the publication of new peer-reviewed research in Frontiers in Digital Health demonstrating substantial and sustained blood glucose improvements among users of the Dario platform. 
The observational study, titled "Machine learning and engagement insights for personalized blood glucose management," analyzed real-world data from 22,414 adults with type 2 diabetes and baseline blood glucose levels in the high-risk range. Using advanced machine learning ("ML") models and longitudinal mixed-effects analyses, researchers identified distinct glycemic trajectories moderated by demographic, clinical and engagement factors.By applying generalized linear mixed-effects tree models, researchers uncovered key moderating factors that influence glycemic improvement. Importantly, outcomes suggested broad across diverse user populations, as demonstrated with no meaningful body mass index ("BMI") difference across ethnicities.  Higher levels of digital engagement – specifically frequent blood glucose monitoring and lifestyle activities tags – were associated with stronger, more durable glycemic improvements.  A key, actionable insight identified 12 measurements per month as a threshold of glycemic improvement. "Our findings reinforce that engagement is not just a usage metric – it is a clinical signal," said Yifat Hershcovitz, PhD, VP Clinical & Scientific Affairs at Dario and senior author of the study. "We observed a substantial early reduction in blood glucose followed by sustained stabilization, particularly among users who monitored consistently and engaged with lifestyle tools. Machine learning enables us to translate these patterns into adaptive, data-driven strategies that optimize long-term diabetes management.""This study demonstrates that digital health platforms can move beyond one-size-fits-all approaches," said Omar Manejwala, MD, Chief Medical Officer of Dario. "By applying machine learning to real-world data at scale, we can identify which users respond best, when intervention is most impactful and how engagement behaviors influence outcomes. These insights allow us to personalize support dynamically and improve blood glucose management in a clinically meaningful way." For employers, health plans and risk-bearing provider organizations seeking scalable, evidence-based solutions, the published findings underscore Dario's ability to translate real-world data into measurable clinical impact for clients. About DarioHealth Corp. (NASDAQ: DRIO)
DarioHealth Corp. (NASDAQ: DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multi-chronic condition digital therapeutics platform. Dario's platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health.Dario's user-centric platform offers people continuous and customized care for their health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention and results and making the right thing to do the easy thing to do.Dario provides its highly user-rated solutions globally to health plans and other payers, self-insured employers, providers of care and consumers. To learn more about Dario and its digital health solutions, or for more information, visit http://dariohealth.com. Cautionary Note Regarding Forward-Looking StatementsThis news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses the potential benefits of its platforms, that the engagement data provides clinical signals that could impact ROI and may improve long-term glycemic outcomes, and that machine learning analytics may enable more adaptive and personalized care strategies.. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.DarioHealth Corporate ContactsMichael Lipari
SVP Corporate Development
irteam @W. Mark-785-6310Rob Halpern
SVP Marketing
irteam@dariohealth.comLogo  - https://mma.prnewswire.com/media/2866807/Dario_Logo.jpg



View original content:https://www.prnewswire.com/news-releases/dario-demonstrates-clinically-meaningful-blood-glucose-improvements-and-personalized-glycemic-trajectories-across-22-000-users-machine-learning-study-findings-published-in-frontiers-in-digital-health-302707687.htmlSOURCE DarioHealth Corp.

Original: Dario Demonstrates Clinically Meaningful Blood Glucose Improvements and Personalized Glycemic Trajectories Across 22,000+ Users: Machine Learning Study Findings Published in Frontiers in Digital Health

DRIO: The 'DARIO BROTHERS' again. What firm is NOT launching this purportedly-DISRUPTIVE, Quantum-AI-Patient-Monitoring-&-Personalized-Therapeutics-&-Everything-Else-Technology, stuff??!!! (Don't like their FLOAT.)

Looking good today $1.23 + 50%
NEW YORK--(BUSINESS WIRE)--Jan. 14, 2025--Market News Alerts Updates that DarioHealth Corp. (Nasdaq: DRIO) is taking another bold step into the rapidly growing weight-loss market, now projected to exceed $100 billion annually by 2030. The company’s latest move expands its GLP-1 offering with prescribing capabilities, positioning Dario to capture a larger share of this lucrative space as demand for medical weight-loss solutions skyrockets across employers and consumers. Following the announcement, Dario’s shares surged nearly 14%, reflecting investor excitement over this significant growth opportunity.The market for GLP-1 medications, driven by blockbuster drugs like Novo Nordisk’s Ozempic and Wegovy, is transforming how obesity and weight management are addressed. These medications have shown impressive results, leading to double-digit weight loss, but the rising costs are pushing employers to seek solutions that ensure better ROI. With 44% of large employers now covering obesity medications, according to a recent Mercer survey, Dario’s expanded offering provides an end-to-end program to improve employee health outcomes while managing costs.Unlike many digital health providers, Dario’s solution integrates behavior change programs with physician oversight, ensuring that GLP-1 medications are prescribed to the right people and supported by sustainable lifestyle changes. This approach aims to prevent the all-too-common cycle of weight regain after medication use, a key concern for both individuals and employers. The new prescribing capability is a critical piece of the puzzle, enabling Dario to oversee the entire weight-loss journey and optimize long-term results.Beyond employers, the direct-to-consumer market is another high-growth target for Dario. As more consumers seek out medical weight-loss options online, the company’s digital platform, combined with virtual care, offers an easily accessible, scalable solution to meet this demand. Additionally, pharmaceutical companies are increasingly seeking partners like Dario to provide data-driven insights and improve patient engagement, opening potential new revenue streams.Dario’s move follows the success of GLP-1 giants Novo Nordisk and Eli Lilly, whose treatments have reshaped the market. However, while the market leaders focus on medications alone, Dario’s behavior-first model differentiates it by tackling the underlying habits that drive lasting weight loss.As the GLP-1 market continues to expand, Dario’s integrated solution could position the company as a key digital health partner for employers, consumers, and pharma companies alike—tapping into one of healthcare’s most promising opportunities for growth.Market Alerts are generated by Wall Street Wire’s news desk and summarize news developments. They include partner content on behalf of the mentioned issuer [DRIO]. They are not intended to serve as financial or investment advice. Please see our full terms, disclaimers and compensation disclosures here: redditwire.com/terms. Our alerts may include forward looking statements about the significance or impact an announcement or development may have on the future of a company or industry as well as other similar statements which may not come to fruition. We advise all readers refer to our full terms in the above link.View source version on businesswire.com: https://www.businesswire.com/news/home/20250114486200/en/Market Alerts News Desk
media.globalmarkets@gmail.com

$25??? How did tht work out for u

I know, I add 3000 shares today and hope it's gonna stay that level for me tomorrow to add more.

wow look at DRIO, it totally collapsed, I ended up doing pretty decent considering its fall from grace even down to 3 bucks, but, the scary part is had I had enough free cash to buy back in from say $3 to $1 I would probably have done so, this is just utter devastation of a stock that has real revenues and real impact on peoples lives, I literally cannot believe it. At a buck it sure seems like a friggin steal

well some of those calls finished in the money over 5 bucks and I was called out, perfect, continuing with the Dec options. Granted the DRIO options dont give a ton of premium considering the potential in the stock from where it has fallen, but so be it, if you buy the stock cheap then it just doesnt matter. DRIO is a good trade down here.

DRIOs been a tough trade for the last 10 months or so, but still have been able to make a few bucks overall, the stock long term is oversold compared to the rest of the market. Most recently I wrote the 5.0 calls for Oct and Nov hoping for them to go out worthless, but even if not, it will be profit if I am called out anywhere in the money. In this market you need to take profits as they come, and writing the options can be good. I would even consider writing the $5 puts, though all of this takes valuable margin so need to be prudent.

DRIO has had a nice run and I have taken a lot off the table. In a market like this, need to shift things around especially on upside like this in a short period, can always re-enter if it pulls back significantly.

wow DRIO has really tanked, imagine from the 30s down to 5 dollar range, wow. I have done some trading and have an average around 7.50 since first purchase at 12.65, not bad, but you can never pick the bottom of any of these they always go further than you think is possible, I am fine with that. DRIO at 6 bucks is a great price.

Trading DRIO again, starting at 10 bucks, it's an excellent price under 8 and i will definitely try and accumulate at these levels.

Wow DRIO is an absolute steal at these prices. I dont have the money to put in this second, but I would certainly consider it.

Looking to gain today.

Brilliant acquisition of Upright that further differentiates DRIO from competitors such as Livongo.

Market has not yet appreciated the value of adding the leading MSK platform to DRIO's own platform.

The concurrent investment by leading bioscience institutional investors, such as Perceptive, at market price, is also very positive news, and further validates the value and potential of this company.

One more time bought back in the 16s avg and sold off everything as of today, I am done with DRIO unless it has another decent pullback, dont know if it will or not. There was a ton of money to be made on DRIO, I did ok but could have done a lot lot better considering how long I had been in it, but I'll take it.

sold my last shares at $20, DRIO has been good to me, but definitely had to persevere and trade, though had I just held I would have done better than all the trading machinations. This no longer is a penny stock and so holding it has less huge potential in my opinion. But any large pullbacks starting around here I am willing to dabble and buy some back in.

Not really...

I’d hold and hope for another pop. Several are pumping it on Twitter.

Question on DRIOW?!?

I purchased DRIOW last week at $0.43 average share price. I won 41808 shares at this average.

When I reached out to IR they said that the effective share price is $86.60 due to the 20 to 1 Reverse split in November of 2019.

I'd like to understand if I should cut my losses (made a mistake did not do my DD and thought this was common stock and not Warrants) and sell now or if this will work in my favor?

Thanks for the help!

DRIO is going to $25 in Jan. and DRIOW going to $3.

DRIOW was even high as $1.2 some time ago. LOL!

DRIOW, went high as $0.56 this morning. Amazing!!!

Sold some DRIOW (bought at $0.05 ) for 500% profits and leave the free shares to run.

Bought bunches DRIOW at $0.04-0.05, now 500% gains !!!!!

WOOHOOOOOOO DRIOW$$ LMFAO WOOHOOOOOOOO

News: $DRIO BioMedNewsBreaks - DarioHealth Corp. (NASDAQ: DRIO) Taking Health Care Home Through Innovative Platform

DarioHealth (NASDAQ: DRIO) , a global digital-therapeutics company serving its users with dynamic mobile-health solutions, is a clear point-of-need innovator in today’s standoffish environment. The company supplies hospitals with next-generation technology to provide patients necessary...

Got this from DRIO - BioMedNewsBreaks - DarioHealth Corp. (NASDAQ: DRIO) Taking Health Care Home Through Innovative Platform

News: $DRIO NetworkNewsBreaks - Shares of DarioHealth Corp. (NASDAQ: DRIO) Reach 52-Week High

Shares of DarioHealth Corp. (NASDAQ: DRIO) , a pioneer in the global digital therapeutics market, reached a new 52-week high on Wednesday. In morning trading, the company’s shares reached a peak of $22.49 on volume of over 170,000, up from an opening price of $18.75. At time of publish...

Read the whole news DRIO - NetworkNewsBreaks - Shares of DarioHealth Corp. (NASDAQ: DRIO) Reach 52-Week High

Shouldn't the warrants be worth at least $5 WOOHOOOOOOOOOOOOOOO DRIO $28 TARGET price

News: $DRIO BioMedNewsBreaks - Aegis Capital Corp. Initiates Coverage, Issues 'Buy' Rating on DarioHealth Corp. (NASDAQ: DRIO)

Aegis Capital Corp. has initiated coverage with a ‘Buy’ rating and price target of $25 on shares of DarioHealth’s (NASDAQ: DRIO) stock. DRIO is a pioneer in the global digital therapeutics (“DTx”) industry with its popular, smartphone-centered personalize...

In case you are interested DRIO - BioMedNewsBreaks - Aegis Capital Corp. Initiates Coverage, Issues 'Buy' Rating on DarioHealth Corp. (NASDAQ: DRIO)

Big Move upcoming WOOHOOOOOOOOOOOOOOO DRIO DRIOW

woohooooooooooooooo

DRIO $28 TARGET PRICE WOOHOOOOOOOOOOOOOOO

DRIO $28 TARGET PRICE WOOHOOOOOOOOOOOOOOO

2021

Warrant way too cheap DRIOW

Hey,
im interested in the Drio Warrants does anyone know the Terms of Warrants, Exercise price and Expiration date.

$$$$$$$

I got some of the warrant
Wayyy undervalued

DRIOW warrant

This move is huge WOW!

WOW!NICE

DRIO WOOHOOOOOOOOOOOOOOOO

DRIOW

What are the warrants?